An Open Label Phase 2 Study of Itacitinib (INCB039110) in Combination with Low Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects with Myelofibrosis

IRB/UVA Tracking #
20183
Contact
Contact Phone
Phase
II
Primary purpose
Treatment
Cancer PI
Michael Keng
Status
OPEN TO ACCRUAL
Ages
Adult